Does the media refer more to KRYS or NAMS?

In the previous week, NewAmsterdam Pharma had 4 more articles in the media than Krystal Biotech. MarketBeat recorded 6 mentions for NewAmsterdam Pharma and 2 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.25 beat NewAmsterdam Pharma's score of 0.14 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NewAmsterdam Pharma 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor KYMR or NAMS?

In the previous week, NewAmsterdam Pharma had 2 more articles in the media than Kymera Therapeutics. MarketBeat recorded 6 mentions for NewAmsterdam Pharma and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.34 beat NewAmsterdam Pharma's score of 0.14 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NewAmsterdam Pharma 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NAMS or ARWR?

In the previous week, NewAmsterdam Pharma and NewAmsterdam Pharma both had 6 articles in the media. Arrowhead Pharmaceuticals' average media sentiment score of 0.17 beat NewAmsterdam Pharma's score of 0.14 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arrowhead Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IBRX or NAMS?

In the previous week, ImmunityBio had 3 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 9 mentions for ImmunityBio and 6 mentions for NewAmsterdam Pharma. ImmunityBio's average media sentiment score of 0.67 beat NewAmsterdam Pharma's score of 0.14 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PTGX or NAMS?

In the previous week, NewAmsterdam Pharma had 4 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 6 mentions for NewAmsterdam Pharma and 2 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.83 beat NewAmsterdam Pharma's score of 0.14 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

NewAmsterdam Pharma (NAMS) Competitors

$23.05 -1.11 (-4.60%)

As of 03:46 PM Eastern

Compare

NAMS vs. KRYS, KYMR, ARWR, IBRX, and PTGX

Should you buy NewAmsterdam Pharma stock or one of its competitors? NewAmsterdam Pharma's main competitors and comparable companies include Krystal Biotech (KRYS), Kymera Therapeutics (KYMR), Arrowhead Pharmaceuticals (ARWR), ImmunityBio (IBRX), and Protagonist Therapeutics (PTGX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NewAmsterdam Pharma compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and NewAmsterdam Pharma (NASDAQ:NAMS) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Krystal Biotech has a net margin of 54.82% compared to NewAmsterdam Pharma's net margin of -3,644.21%. Krystal Biotech's return on equity of 19.34% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%

Krystal Biotech has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	24.99	$204.83M	$7.98	41.17
NewAmsterdam Pharma	$22.50M	123.93	-$203.82M	-$2.16	N/A

Krystal Biotech has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market.

Krystal Biotech currently has a consensus price target of $377.20, indicating a potential upside of 14.81%. NewAmsterdam Pharma has a consensus price target of $49.73, indicating a potential upside of 113.17%. Given NewAmsterdam Pharma's higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

In the previous week, NewAmsterdam Pharma had 4 more articles in the media than Krystal Biotech. MarketBeat recorded 6 mentions for NewAmsterdam Pharma and 2 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.25 beat NewAmsterdam Pharma's score of 0.14 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NewAmsterdam Pharma	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Krystal Biotech beats NewAmsterdam Pharma on 12 of the 16 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and NewAmsterdam Pharma (NASDAQ:NAMS) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

NewAmsterdam Pharma has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	232.12	-$311.35M	-$3.24	N/A
NewAmsterdam Pharma	$22.50M	123.93	-$203.82M	-$2.16	N/A

Kymera Therapeutics has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market.

In the previous week, NewAmsterdam Pharma had 2 more articles in the media than Kymera Therapeutics. MarketBeat recorded 6 mentions for NewAmsterdam Pharma and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.34 beat NewAmsterdam Pharma's score of 0.14 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NewAmsterdam Pharma	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kymera Therapeutics currently has a consensus target price of $133.21, indicating a potential upside of 21.70%. NewAmsterdam Pharma has a consensus target price of $49.73, indicating a potential upside of 113.17%. Given NewAmsterdam Pharma's higher possible upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.88
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Kymera Therapeutics has a net margin of -285.33% compared to NewAmsterdam Pharma's net margin of -3,644.21%. Kymera Therapeutics' return on equity of -21.22% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%

Summary

Kymera Therapeutics beats NewAmsterdam Pharma on 10 of the 16 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Arrowhead Pharmaceuticals?

NewAmsterdam Pharma (NASDAQ:NAMS) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

Arrowhead Pharmaceuticals has higher revenue and earnings than NewAmsterdam Pharma. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	123.93	-$203.82M	-$2.16	N/A
Arrowhead Pharmaceuticals	$829.45M	11.02	-$1.63M	-$2.25	N/A

NewAmsterdam Pharma presently has a consensus price target of $49.73, indicating a potential upside of 113.17%. Arrowhead Pharmaceuticals has a consensus price target of $98.31, indicating a potential upside of 51.44%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, NewAmsterdam Pharma and NewAmsterdam Pharma both had 6 articles in the media. Arrowhead Pharmaceuticals' average media sentiment score of 0.17 beat NewAmsterdam Pharma's score of 0.14 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arrowhead Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NewAmsterdam Pharma has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market.

Arrowhead Pharmaceuticals has a net margin of -47.79% compared to NewAmsterdam Pharma's net margin of -3,644.21%. NewAmsterdam Pharma's return on equity of -34.81% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

NewAmsterdam Pharma beats Arrowhead Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

NewAmsterdam Pharma has lower revenue, but higher earnings than ImmunityBio. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	97.99	-$351.40M	-$0.97	N/A
NewAmsterdam Pharma	$22.50M	123.93	-$203.82M	-$2.16	N/A

ImmunityBio has a net margin of -598.55% compared to NewAmsterdam Pharma's net margin of -3,644.21%. ImmunityBio's return on equity of 0.00% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%

ImmunityBio has a beta of 0.02, suggesting that its stock price is 98% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market.

In the previous week, ImmunityBio had 3 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 9 mentions for ImmunityBio and 6 mentions for NewAmsterdam Pharma. ImmunityBio's average media sentiment score of 0.67 beat NewAmsterdam Pharma's score of 0.14 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ImmunityBio currently has a consensus price target of $14.20, indicating a potential upside of 35.56%. NewAmsterdam Pharma has a consensus price target of $49.73, indicating a potential upside of 113.17%. Given NewAmsterdam Pharma's higher probable upside, analysts plainly believe NewAmsterdam Pharma is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 66.1% of ImmunityBio shares are held by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

ImmunityBio beats NewAmsterdam Pharma on 9 of the 16 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and NewAmsterdam Pharma (NASDAQ:NAMS) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

Protagonist Therapeutics has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market.

Protagonist Therapeutics currently has a consensus price target of $147.13, indicating a potential upside of 5.24%. NewAmsterdam Pharma has a consensus price target of $49.73, indicating a potential upside of 113.17%. Given NewAmsterdam Pharma's higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Protagonist Therapeutics has a net margin of 29.40% compared to NewAmsterdam Pharma's net margin of -3,644.21%. Protagonist Therapeutics' return on equity of 12.03% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%

In the previous week, NewAmsterdam Pharma had 4 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 6 mentions for NewAmsterdam Pharma and 2 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.83 beat NewAmsterdam Pharma's score of 0.14 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Protagonist Therapeutics has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	196.58	-$130.15M	$1.03	135.73
NewAmsterdam Pharma	$22.50M	123.93	-$203.82M	-$2.16	N/A

Summary

Protagonist Therapeutics beats NewAmsterdam Pharma on 13 of the 17 factors compared between the two stocks.

Get NewAmsterdam Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAMS vs. The Competition

Export

Metric	NewAmsterdam Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.72B	$3.83B	$7.11B	$13.24B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-10.54	13.45	274.71	26.06
Price / Sales	121.03	1,284.75	600.46	89.74
Price / Cash	N/A	121.76	77.38	51.25
Price / Book	3.82	16.62	10.93	6.32
Net Income	-$203.82M	-$22.67M	$3.50B	$361.55M
7 Day Performance	0.89%	-3.21%	-2.21%	-1.67%
1 Month Performance	-10.98%	-10.88%	-6.45%	-3.94%
1 Year Performance	-25.80%	21.05%	8.70%	2.75%

NewAmsterdam Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAMS NewAmsterdam Pharma	3.6011 of 5 stars	$23.09 -4.4%	$49.73 +115.4%	-17.7%	$2.76B	$22.50M	N/A	100
KRYS Krystal Biotech	4.0372 of 5 stars	$350.88 +5.1%	$365.80 +4.3%	+81.1%	$10.39B	$389.13M	43.97	295
KYMR Kymera Therapeutics	2.0088 of 5 stars	$122.06 +3.7%	$133.21 +9.1%	+101.5%	$10.15B	$39.21M	N/A	273	Insider Trade
ARWR Arrowhead Pharmaceuticals	2.9549 of 5 stars	$71.86 +4.5%	$99.15 +38.0%	+85.1%	$10.12B	$829.45M	N/A	711
IBRX ImmunityBio	2.8417 of 5 stars	$9.29 +9.9%	$14.20 +52.9%	+274.2%	$9.85B	$113.29M	N/A	691

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAMS) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NewAmsterdam Pharma (NAMS) Competitors

NAMS vs. KRYS, KYMR, ARWR, IBRX, and PTGX

How does NewAmsterdam Pharma compare to Krystal Biotech?

Summary

How does NewAmsterdam Pharma compare to Kymera Therapeutics?

Summary

How does NewAmsterdam Pharma compare to Arrowhead Pharmaceuticals?

Summary

How does NewAmsterdam Pharma compare to ImmunityBio?

Summary

How does NewAmsterdam Pharma compare to Protagonist Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAMS vs. The Competition

NewAmsterdam Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NewAmsterdam Pharma (NAMS) Competitors

NAMS vs. KRYS, KYMR, ARWR, IBRX, and PTGX

How does NewAmsterdam Pharma compare to Krystal Biotech?

Is KRYS or NAMS more profitable?

Which has stronger valuation and earnings, KRYS or NAMS?

Which has more volatility and risk, KRYS or NAMS?

Do analysts rate KRYS or NAMS?

Does the media refer more to KRYS or NAMS?

Do institutionals and insiders believe in KRYS or NAMS?

Summary

How does NewAmsterdam Pharma compare to Kymera Therapeutics?

Which has higher valuation and earnings, KYMR or NAMS?

Which has more risk & volatility, KYMR or NAMS?

Does the media favor KYMR or NAMS?

Do insiders and institutionals have more ownership in KYMR or NAMS?

Do analysts rate KYMR or NAMS?

Is KYMR or NAMS more profitable?

Summary

How does NewAmsterdam Pharma compare to Arrowhead Pharmaceuticals?

Which has higher earnings and valuation, NAMS or ARWR?

Do analysts prefer NAMS or ARWR?

Does the media favor NAMS or ARWR?

Which has more risk & volatility, NAMS or ARWR?

Is NAMS or ARWR more profitable?

Do insiders & institutionals have more ownership in NAMS or ARWR?

Summary

How does NewAmsterdam Pharma compare to ImmunityBio?

Which has better valuation & earnings, IBRX or NAMS?

Is IBRX or NAMS more profitable?

Which has more risk & volatility, IBRX or NAMS?

Does the media favor IBRX or NAMS?

Do analysts prefer IBRX or NAMS?

Do institutionals and insiders have more ownership in IBRX or NAMS?

Summary

How does NewAmsterdam Pharma compare to Protagonist Therapeutics?

Which has more risk and volatility, PTGX or NAMS?

Do analysts prefer PTGX or NAMS?

Is PTGX or NAMS more profitable?

Does the media favor PTGX or NAMS?

Do insiders and institutionals believe in PTGX or NAMS?

Which has stronger valuation and earnings, PTGX or NAMS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAMS vs. The Competition

NewAmsterdam Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools